Drug intelligence / Profile preview

REGN9533

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

REGN9533 is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals. It targets blood coagulation factor XII and acts as a factor XII inhibitor. The drug is being studied for the prevention and treatment of thromboembolic diseases, including venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE). As an antithrombotic agent, its mechanism aims to prevent excessive blood clotting while minimizing bleeding risk compared to traditional anticoagulants. REGN9533 is currently in early clinical development, with Phase 1 trials planned to assess safety and tolerability in healthy volunteers[2][3][4].

Other names: REGN 9533REGN9533REGN-9533

Targets

F12 (Coagulation Factor XII)

Beyond the preview

Go deeper on REGN9533.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN9533.

Explore the full profile